search button

The utility of serum N-ERC/mesothelin as a biomarker of ovarian carcinoma

  • Authors:
    • Harumi Saeki
    • Akane Hashizume
    • Hiroshi Izumi
    • Fujihiko Suzuki
    • Kazuhisa Ishi
    • Michio Nojima
    • Masahiro Maeda
    • Okio Hino

  • View Affiliations

  • Published online on: July 11, 2012     https://doi.org/10.3892/ol.2012.796
  • Pages: 637-641
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Ovarian carcinoma has been difficult to diagnose at an early stage. Recently, it has been recognized that the measurement of blood N-ERC/mesothelin levels aids early detection in and postoperative therapeutic monitoring of patients with mesothelioma, who have been exposed to asbestos. ERC/mesothelin has also been reported to be expressed in ovarian carcinoma. We determined serum N-ERC/mesothelin levels in patients with ovarian carcinoma using an enzyme‑linked immunosorbent assay (ELISA). In addition, we immunohistochemically evaluated surgically resected specimens for C-ERC/mesothelin expression. As a result, of the 32 patients with ovarian tumors (18 carcinoma, 2 borderline tumors), one patient with serous adenocarcinoma showed increased N-ERC/mesothelin levels. Immunohistochemically, of the 20 ovarian tumor (carcinoma and borderline tumor) specimens evaluated for serum N-ERC/mesothelin, 9 (45.0%) were positive for C-ERC/mesothelin. The C-ERC/mesothelin-positive specimens were found to be serous and clear cell adenocarcinomas. If serum N-ERC/mesothelin, which is considered useful for early detection in and therapeutic monitoring of patients with mesothelioma, may also be used for ovarian carcinoma monitoring, it may be a valuable serum tumor marker for the early detection of ovarian carcinoma.
View Figures
View References

Related Articles

Journal Cover

October 2012
Volume 4 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Saeki H, Hashizume A, Izumi H, Suzuki F, Ishi K, Nojima M, Maeda M and Hino O: The utility of serum N-ERC/mesothelin as a biomarker of ovarian carcinoma. Oncol Lett 4: 637-641, 2012.
APA
Saeki, H., Hashizume, A., Izumi, H., Suzuki, F., Ishi, K., Nojima, M. ... Hino, O. (2012). The utility of serum N-ERC/mesothelin as a biomarker of ovarian carcinoma. Oncology Letters, 4, 637-641. https://doi.org/10.3892/ol.2012.796
MLA
Saeki, H., Hashizume, A., Izumi, H., Suzuki, F., Ishi, K., Nojima, M., Maeda, M., Hino, O."The utility of serum N-ERC/mesothelin as a biomarker of ovarian carcinoma". Oncology Letters 4.4 (2012): 637-641.
Chicago
Saeki, H., Hashizume, A., Izumi, H., Suzuki, F., Ishi, K., Nojima, M., Maeda, M., Hino, O."The utility of serum N-ERC/mesothelin as a biomarker of ovarian carcinoma". Oncology Letters 4, no. 4 (2012): 637-641. https://doi.org/10.3892/ol.2012.796